Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
OCUL Ocular Therapeutix, Inc. daily Stock Chart
OCUL [NASD]
Ocular Therapeutix, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-1.80 Insider Own10.98% Shs Outstand45.61M Perf Week-0.96%
Market Cap234.44M Forward P/E- EPS next Y-1.04 Insider Trans0.70% Shs Float42.80M Perf Month9.59%
Income-77.80M PEG- EPS next Q-0.43 Inst Own53.20% Short Float14.33% Perf Quarter82.59%
Sales2.50M P/S93.77 EPS this Y28.50% Inst Trans9.34% Short Ratio9.70 Perf Half Y9.59%
Book/sh0.24 P/B21.42 EPS next Y41.20% ROA-88.10% Target Price6.40 Perf Year23.56%
Cash/sh1.43 P/C3.58 EPS next 5Y- ROE-383.60% 52W Range2.35 - 5.82 Perf YTD30.13%
Dividend- P/FCF- EPS past 5Y-19.40% ROI-97.40% 52W High-14.77% Beta2.43
Dividend %- Quick Ratio6.20 Sales past 5Y- Gross Margin35.20% 52W Low111.06% ATR0.30
Employees167 Current Ratio6.30 Sales Q/Q60.00% Oper. Margin- RSI (14)48.74 Volatility6.80% 5.44%
OptionableYes Debt/Eq0.00 EPS Q/Q-4.00% Profit Margin- Rel Volume1.11 Prev Close5.14
ShortableYes LT Debt/Eq4.26 EarningsMar 05 AMC Payout- Avg Volume632.69K Price4.96
Recom2.20 SMA200.08% SMA508.27% SMA20022.87% Volume398,539 Change-3.50%
May-21-19Reiterated H.C. Wainwright Buy $12 → $9
May-21-19Downgrade Raymond James Strong Buy → Outperform $11 → $5
May-21-19Downgrade Cowen Outperform → Market Perform $13 → $3
Dec-03-18Reiterated Cantor Fitzgerald Overweight $22 → $24
Nov-15-18Initiated Raymond James Strong Buy $10
Sep-07-18Initiated Piper Jaffray Overweight
Oct-24-17Initiated Guggenheim Buy $12
Jul-26-17Initiated H.C. Wainwright Buy $10
Jul-12-17Reiterated Cantor Fitzgerald Overweight $35 → $21
Jun-23-17Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-10-17Initiated Cantor Fitzgerald Overweight $35
Nov-15-16Reiterated RBC Capital Mkts Outperform $30 → $32
Aug-11-16Initiated JMP Securities Mkt Outperform
Feb-17-16Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-23-15Downgrade Morgan Stanley Overweight → Equal-Weight
Aug-13-15Initiated Morgan Stanley Overweight $24
Aug-05-15Initiated Nomura Buy $46
Apr-08-15Reiterated RBC Capital Mkts Outperform $50 → $48
Mar-11-15Reiterated RBC Capital Mkts Outperform $35 → $50
Mar-11-15Reiterated Oppenheimer Outperform $42 → $49
Feb-25-20 08:00AM  Ocular Therapeutix to Present at the Cowen and Company 40th Annual Health Care Conference Business Wire
Feb-23-20 07:10AM  3 Monster Growth Stocks Primed for Further Gains TipRanks
Feb-18-20 08:10AM  Loss-Making Ocular Therapeutix, Inc. (NASDAQ:OCUL) Expected To Breakeven Simply Wall St.
Feb-07-20 08:00AM  Ocular Therapeutix Presents Data Demonstrating a Clinically-Meaningful Reduction in Intraocular Pressure in Patients with Primary Open Angle Glaucoma or Ocular Hypertension Treated with OTX-TIC at Glaucoma 360 Conference Business Wire +7.87%
Jan-13-20 01:34PM  Is Ocular Therapeutix, Inc. (NASDAQ:OCUL) Overpaying Its CEO? Simply Wall St.
Dec-23-19 03:58PM  Did Hedge Funds Drop The Ball On Ocular Therapeutix Inc (OCUL) ? Insider Monkey +6.22%
Dec-06-19 02:20PM  Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way? Simply Wall St.
Dec-04-19 05:56PM  Edited Transcript of OCUL earnings conference call or presentation 12-Nov-19 1:00pm GMT Thomson Reuters StreetEvents
Nov-26-19 08:00AM  Ocular Therapeutix to Present at the Piper Jaffray 31st Annual Healthcare Conference TEST Business Wire Releases
08:00AM  Ocular Therapeutix to Present at the Piper Jaffray 31st Annual Healthcare Conference Business Wire
Nov-14-19 08:00AM  Ocular Therapeutix to Present at the Jefferies 2019 London Healthcare Conference Business Wire
Nov-12-19 08:15AM  Ocular Therapeutix (OCUL) Reports Q3 Loss, Misses Revenue Estimates Zacks -12.29%
07:00AM  Ocular Therapeutix Reports Third Quarter 2019 Financial Results and Business Update Business Wire
Nov-08-19 04:01PM  Ocular Therapeutix Announces Strategic Update and Operational Restructuring Business Wire
Nov-05-19 08:00AM  Ocular Therapeutix To Report Third Quarter 2019 Financial Results Business Wire
07:00AM  Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Oct-30-19 10:33AM  Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-15-19 11:38AM  Moving Average Crossover Alert: Ocular Therapeutix Zacks +7.84%
Oct-01-19 04:24PM  Ocular Therapeutix Announces Permanent J-Code for DEXTENZA® (dexamethasone ophthalmic insert) Effective October 1, 2019 Business Wire
11:01AM  These 9 Massachusetts companies rank among the 'happiest' in the country American City Business Journals
Sep-26-19 08:00AM  Ocular Therapeutix to Present at the 2019 Cantor Global Healthcare Conference Business Wire -10.34%
Sep-24-19 08:00AM  Ocular Therapeutix Announces First Patient Dosed in Phase 3 Clinical Trial of DEXTENZA® for the Treatment of Allergic Conjunctivitis Business Wire -6.03%
Aug-29-19 08:00AM  Ocular Therapeutix to Present at the 2019 Wells Fargo Healthcare Conference Business Wire
Aug-23-19 11:24AM  Keep Your Eye on These 4 Healthcare Stocks Motley Fool -5.54%
Aug-15-19 10:15PM  Edited Transcript of OCUL earnings conference call or presentation 7-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-14-19 11:56AM  Read This Before Selling Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Simply Wall St. -5.99%
Aug-07-19 06:15PM  Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:01PM  Ocular Therapeutix Reports Second Quarter 2019 Financial Results and Business Update Business Wire
Jul-30-19 10:38AM  Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-26-19 08:00AM  Ocular Therapeutix Announces Early Assignment of Permanent and Specific J-Code (J1096) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg by the Centers for Medicare and Medicaid Services Business Wire +11.21%
Jul-18-19 06:26PM  Allergan Announces FDA Acceptance of Glaucoma Candidate NDA Zacks
Jul-11-19 04:05PM  Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
04:01PM  Ocular Therapeutix Announces Christopher White as Senior Vice President, Head of Business and Corporate Development Business Wire
Jul-09-19 08:00AM  Ocular Therapeutix Announces Patricia Kitchen as Chief Operations Officer Business Wire
Jul-08-19 08:42AM  Implied Volatility Surging for Ocular (OCUL) Stock Options Zacks
Jul-01-19 08:00AM  Ocular Therapeutix Announces Commercial Launch of DEXTENZA® (dexamethasone intracanalicular insert) 0.4 mg for Ophthalmic Use in the United States Business Wire
Jun-24-19 08:50AM  Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza Zacks
Jun-23-19 03:53PM  Bulls And Bears Of The Week: Tyson, Tesla, Crocs And More Benzinga
Jun-21-19 11:19AM  FDA OKs Expanded Indication For Ocular Therapeutix Eye Pain Drug Months Ahead Of Schedule Benzinga +7.02%
08:00AM  Ocular Therapeutix Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (0.4 Dexamethasone Intracanalicular Insert for Ophthalmic Use) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery Business Wire
Jun-10-19 07:15PM  Ocular Therapeutix Inc (OCUL) President & CEO Antony C. Mattessich Bought $112,400 of Shares GuruFocus.com
09:53AM  Does Market Volatility Impact Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) Share Price? Simply Wall St.
May-31-19 08:44AM  Options Traders Expect Huge Moves in Ocular (OCUL) Stock Zacks +17.89%
May-30-19 08:00AM  Ocular Therapeutix to Present at Three Upcoming Investor Conferences Business Wire -5.38%
May-29-19 08:00AM  Ocular Therapeutix Announces Receipt of C-Code and Pass-Through Payment Status for DEXTENZA® Business Wire
May-23-19 11:26PM  Edited Transcript of OCUL earnings conference call or presentation 10-May-19 12:30pm GMT Thomson Reuters StreetEvents -7.17%
May-21-19 05:36PM  Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint Zacks -22.55%
01:00PM  Raymond James Downgrades Ocular Therapeutix, Remains Bullish On Pipeline Benzinga
May-20-19 11:55PM  Chevron, Sprint, Ocular Therapeutix, and More: Why These Stocks Are in the Spotlight Insider Monkey
04:05PM  Ocular Therapeutix Announces Topline Results of Phase 3 Clinical Trial of OTX-TP for the Treatment of Glaucoma Business Wire
May-10-19 08:45AM  Ocular Therapeutix (OCUL) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:37AM  Ocular Therapeutix: 1Q Earnings Snapshot Associated Press
07:30AM  Ocular Therapeutix Reports First Quarter 2019 Financial Results and Business Update Business Wire
May-03-19 10:30AM  Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out for Zacks
May-02-19 08:00AM  Ocular Therapeutix To Report First Quarter 2019 Financial Results Business Wire
May-01-19 08:30AM  Ocular Therapeutix Announces DEXTENZA® (dexamethasone ophthalmic insert) Recommended for Unique J-Code by CMS Business Wire
Apr-30-19 08:00AM  Ocular Therapeutix, Inc. Settles Litigation with Mati Therapeutics, Inc. Business Wire
Apr-24-19 08:00AM  Ocular Therapeutix to Present New Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium Business Wire
Apr-23-19 04:55PM  Ocular Therapeutix Reports Changes to Board of Directors Business Wire +5.46%
Apr-03-19 08:00AM  Ocular Therapeutix to Present at the H.C. Wainwright Global Life Sciences Conference Business Wire
Apr-02-19 08:15AM  Ocular Therapeutix Announces Notification of FDA Acceptance of Supplemental New Drug Submission for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery Business Wire
Mar-26-19 11:51AM  Recro Pharma Falls as FDA Denies Approval to Pain Candidate Zacks
Mar-25-19 08:00AM  Ocular Therapeutix Reports Election of Leslie Williams to Board of Directors Business Wire
Mar-21-19 09:00AM  Ocular Therapeutix to Host 2019 Research & Development Day Business Wire
Mar-14-19 09:34AM  Edited Transcript of OCUL earnings conference call or presentation 7-Mar-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-07-19 08:35PM  Ocular Therapeutix Inc (OCUL) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:01PM  Ocular Therapeutix Reports Fourth Quarter and Year End 2018 Financial Results and Business Update Business Wire
Mar-05-19 08:00AM  Ocular Therapeutix to Present at the Cowen and Company 39th Annual Health Care Conference Business Wire
Mar-01-19 08:00AM  Ocular Therapeutix To Report Fourth Quarter and Year End 2018 Financial Results Business Wire
Feb-22-19 02:40PM  Watch These Four Biotech Stocks Friday ACCESSWIRE +15.24%
Feb-21-19 09:25PM  Ocular Therapeutix Prices $37.5 Million Subordinated Convertible Debt Financing Business Wire
Feb-20-19 08:30AM  Ocular Therapeutix Announces Dosing of First Patient in OTX-TKI (tyrosine kinase inhibitor implant) Phase 1 Clinical Trial for the Treatment of Wet Age-related Macular Degeneration (AMD) Business Wire
Feb-06-19 12:30PM  Is Ocular Therapeutix, Inc. (NASDAQ:OCUL) A Financially Sound Company? Simply Wall St.
Jan-22-19 07:40AM  Detailed Research: Economic Perspectives on Inovalon, Merit Medical, Senseonics, Ocular Therapeutix, The Hartford Financial Services Group, and Synopsys What Drives Growth in Today's Competitive Landscape GlobeNewswire
Jan-11-19 10:32AM  Ocular (OCUL) Submits an sNDA for Eye Pain Drug Dextenza Zacks
08:38AM  The Daily Biotech Pulse: Agile Gives Regulatory Update On Contraceptive Patch, Advaxis Misses Estimates, Ocular Submits sNDA Benzinga
Jan-10-19 04:01PM  Ocular Therapeutix Submits Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery Business Wire
Jan-07-19 09:00AM  Purdue Pharma L.P. and Ocular Therapeutix, Inc. Announce Initiation of Collaborative Research Activities to Evaluate Innovative Formulations for Non-Opioid Treatments for Pain Business Wire
Dec-28-18 08:00AM  Ocular Therapeutix Announces Completion of Debt Refinancing Business Wire +6.72%
Dec-26-18 10:56AM  Edited Transcript of OCUL earnings conference call or presentation 7-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Dec-20-18 11:00AM  Are Insiders Buying Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock? Simply Wall St.
08:00AM  Ocular Therapeutix Added to Nasdaq Biotechnology Index Business Wire
Dec-06-18 08:00AM  Ocular Therapeutix Announces the Hiring of Chad Brines, Vice President, Sales Business Wire +8.20%
Dec-04-18 08:59AM  Options Traders Expect Huge Moves in Ocular Therapeutix (OCUL) Stock Zacks
Dec-03-18 08:23AM  CORRECTING and REPLACING Ocular Therapeutix Announces FDA Approval of DEXTENZA® for the Treatment of Ocular Pain Following Ophthalmic Surgery Business Wire -13.96%
Nov-21-18 08:00AM  Ocular Therapeutix to Present at the 30th Annual Piper Jaffray Healthcare Conference Business Wire
Nov-15-18 06:35PM  H.C. Wainwright Sees over 80% Upside Potential for These Three Biotech Stocks SmarterAnalyst +5.95%
Nov-12-18 07:40AM  Recent Analysis Shows Clovis Oncology, Evertec, Etsy, Ring Energy, Ocular Therapeutix, and Destination Maternity Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-07-18 06:35PM  Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates Zacks
05:36PM  Ocular Therapeutix: 3Q Earnings Snapshot Associated Press
04:01PM  Ocular Therapeutix Reports Third Quarter 2018 Financial Results and Business Update Business Wire
Oct-31-18 08:00AM  Ocular Therapeutix To Report Third Quarter 2018 Financial Results Business Wire
Oct-30-18 10:33AM  Will Ocular Therapeutix (OCUL) Report Negative Earnings Next Week? What You Should Know Zacks -5.08%
Oct-22-18 02:54PM  Ocular Therapeutix (OCUL): ReSure Warning Letter Insignificant to Pipeline, Says Analyst SmarterAnalyst
Oct-19-18 08:09AM  Ocular Therapeutix stock drops 10% after FDA warning letter MarketWatch
07:50AM  Ocular Therapeutix Receives FDA Warning Letter Related to ReSure® Sealant Business Wire
Oct-18-18 08:55AM  Investor Expectations to Drive Momentum within Teradata, Liberty TripAdvisor, CPI Card Group, Cara Therapeutics, Ocular Therapeutix, and G-III Apparel Group, LTD Discovering Underlying Factors of Influence GlobeNewswire
Oct-11-18 12:57PM  Who Owns Ocular Therapeutix Inc (NASDAQ:OCUL)? Simply Wall St.
Oct-10-18 04:26PM  Why Analysts See Solid Upside Potential for Ocular Therapeutix (OCUL), Catalyst Pharmaceuticals (CPRX), and AcelRx (ACRX) SmarterAnalyst -5.62%
Sep-26-18 08:00AM  Ocular Therapeutix to Present at the 2018 Cantor Global Healthcare Conference Business Wire
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery. Its lead product candidate is DEXTENZA (dexamethasone ophthalmic insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases. The company also develops OTX-TP (intracanalicular travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension; OTX-TIC, an intracameral travoprost implant for the reduction of IOP in patients with moderate to severe glaucoma and ocular hypertension; OTX-TKI, an intravitreal tyrosine kinase inhibitor implant for the treatment of wet age-related macular degeneration(AMD); and OTX-IVT, an intravitreal aflibercept implant for the treatment of wet AMD and other back-of-the-eye diseases. Its various preclinical programs include OTX-BPI for the treatment of acute ocular pain; OTX-BSI to treat post-operative Pain, and inflammation and bacterial infection; OTX-KTO for the treatment of allergy; and OTX-CSI to treat chronic dry-eye. The company has strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds to address conditions of the eye. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Opaleye Management Inc.10% OwnerJan 02Buy3.9015,00058,5084,918,500Jan 03 07:45 PM
Opaleye Management Inc.10% OwnerDec 30Buy3.9720,00079,4104,903,500Jan 02 05:15 PM
Williams Leslie J.DirectorJun 14Buy4.404,50019,8004,500Jun 17 07:21 PM
Notman DonaldChief Financial OfficerJun 14Buy4.332,50010,82524,049Jun 17 07:21 PM
Sawhney AmarpreetChairman of the BoardJun 07Buy3.0265,468197,7131,056,031Jun 10 04:55 PM
Sawhney AmarpreetChairman of the BoardJun 06Buy2.8059,000165,200990,563Jun 10 04:55 PM
Mattessich Antony C.President & CEOJun 06Buy2.8140,000112,40097,900Jun 10 04:53 PM
Sawhney AmarpreetChairman of the BoardJun 05Buy2.9132,85295,599931,563Jun 06 06:09 PM
Sawhney AmarpreetChairman of the BoardJun 04Buy2.9212,92837,750898,711Jun 06 06:09 PM
Goldstein Michael H.Chief Medical OfficerMay 28Buy2.5112,00030,12025,686May 30 04:10 PM
Heier Jeffrey S.DirectorMar 15Buy4.1524,00099,60024,000Mar 18 06:20 PM
Goldstein Michael H.Chief Medical OfficerMar 15Buy4.1510,00041,50013,686Mar 18 06:20 PM
LINDSTROM RICHARD L MDDirectorMar 13Buy4.3356,441244,390100,000Mar 14 04:14 PM
open in yahoo | open in reuters | open in google